Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 4:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ribose Clear all
Withdrawn Phase 2 Interventional

Study To Evaluate D-Ribose For The Treatment of Congestive Heart Failure

NCT01858480
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
D-ribose, Placebo
Drug · Other
Lead sponsor
RiboCor, Inc.
Industry
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
20
States / cities
Long Beach, California • Modesto, California • Sylmar, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 23, 2026, 4:39 PM EDT
Completed Phase 2 Interventional

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

NCT01033123
View directory record Official record
Conditions
Ovarian Cancer
Interventions
BSI-201
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 23, 2026, 4:39 PM EDT
Completed Phase 2 Interventional Results available

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

NCT03326193
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Niraparib, Bevacizumab
Drug · Biological
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
29
States / cities
Mobile, Alabama • Anchorage, Alaska • Mesa, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 23, 2026, 4:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparative Study of Three Collagen Membranes: 1 Non-cross-linked and 2 Cross-linked

NCT06944639
View directory record Official record
Conditions
Bone Regeneration
Interventions
Membrane Jason MB GmbH Non-cross-linked (NCL), Membrane BioMend Extend Glutaraldehyde cross-linked, Membrane OSSIX Agile Ribose cross-linked (RCL)
Device
Lead sponsor
Andrea Ravida
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 23, 2026, 4:39 PM EDT
Active, not recruiting Phase 2 Interventional

Niraparib/TTFields in GBM

NCT04221503
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, GBM
Interventions
Niraparib, Optune, Planned surgical resection
Drug · Device · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 23, 2026, 4:39 PM EDT
Completed Phase 1 Interventional

Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT02944396
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
pemetrexed, nivolumab, paclitaxel, veliparib, carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Birmingham, Alabama • Whittier, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 23, 2026, 4:39 PM EDT
Withdrawn Phase 2 Interventional

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

NCT04239014
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Olaparib, Ceralasertib, Placebo to match olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
22
States / cities
Anchorage, Alaska • La Jolla, California • Long Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 23, 2026, 4:39 PM EDT
Recruiting Phase 2 Interventional

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

NCT03990896
View directory record Official record
Conditions
Breast Cancer
Interventions
Talazoparib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 23, 2026, 4:39 PM EDT
Terminated Phase 1 Interventional

CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients

NCT03944902
View directory record Official record
Conditions
Ovarian Cancer, Resistant BRCA Wild-Type Ovarian Cancer
Interventions
Cohort 1: Dose Escalation, Cohort 2: Dose Escalation
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Birmingham, Alabama • San Francisco, California • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Sep 23, 2026, 4:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

NCT02116777
View directory record Official record
Conditions
Adult Solid Neoplasm, Childhood Solid Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Malignant Solid Neoplasm, Refractory Central Nervous System Neoplasm
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib, Temozolomide
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Months to 30 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 23, 2026, 4:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

NCT03150862
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Pamiparib, TMZ, Radiation
Drug · Radiation
Lead sponsor
BeiGene USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
18
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 23, 2026, 4:39 PM EDT
Completed Phase 2 Interventional

EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

NCT04669002
View directory record Official record
Conditions
Ovarian Cancer
Interventions
EP0057, Olaparib tablets
Drug
Lead sponsor
Ellipses Pharma
Industry
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
11
States / cities
Irvine, California • Lady Lake, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Sep 23, 2026, 4:39 PM EDT
Completed Not applicable Interventional Results available

Comparison of Yttrium-90 Absorbed Doses Using PET/CT Versus PET/MR Imaging for Hepatic Malignancies

NCT04332419
View directory record Official record
Conditions
Hepatic Malignancies
Interventions
PET/CT, PET/MR, SIRT with Y-90
Device · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Sep 23, 2026, 4:39 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

NCT03875313
View directory record Official record
Conditions
Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer, CRC, RCC, ccRCC
Interventions
CB-839, Talazoparib
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Sep 23, 2026, 4:39 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

NCT03079687
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Olaparib tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Duarte, California • Newport Beach, California • Roseville, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Sep 23, 2026, 4:39 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

NCT02264990
View directory record Official record
Conditions
Non-squamous Non-small Cell Lung Cancer
Interventions
Paclitaxel, Carboplatin, Cisplatin, Veliparib, Pemetrexed
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
25
States / cities
Huntsville, Alabama • Mobile, Alabama • Springdale, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Sep 23, 2026, 4:39 PM EDT
Terminated Phase 1 Interventional Results available

Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors

NCT01127178
View directory record Official record
Conditions
Solid Tumors
Interventions
E7016 + TMZ
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Boston, Massachusetts • Lebanon, New Hampshire • Greenville, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 23, 2026, 4:39 PM EDT
Terminated Phase 4 Interventional

Ticagrelor and Peripheral Arterial Disease

NCT02407314
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Percutaneous Peripheral Intervention, Optical Coherence Tomography, Ankle Brachial Index, Six minute walk distance, Aspirin, Aspirin + Ticagrelor
Procedure · Device · Other + 1 more
Lead sponsor
Arkansas Heart Hospital
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Sep 23, 2026, 4:39 PM EDT
Completed Phase 1 Interventional

Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer

NCT00515866
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
KU-0059436 (AZD2281)(PARP inhibitor), Gemcitabine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Sep 23, 2026, 4:39 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

NCT05417594
View directory record Official record
Conditions
Advanced Solid Malignancies
Interventions
AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391, Trastuzumab Deruxtecan (T-DXd), Datopotamab Deruxtecan (Dato-DXd)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
11
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 23, 2026, 4:39 PM EDT
Completed Phase 2 Interventional Results available

A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

NCT03414047
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Prexasertib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Tucson, Arizona • Vallejo, California • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Sep 23, 2026, 4:39 PM EDT
Terminated Phase 2 Interventional Results available

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

NCT04538378
View directory record Official record
Conditions
EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine
Interventions
Olaparib, Durvalumab, EKG, Tumor biopsy, CT chest, abdomen and pelvis, MRI chest, abdomen and pelvis
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 23, 2026, 4:39 PM EDT
Completed Phase 1 Interventional Results available

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

NCT02723864
View directory record Official record
Conditions
Neoplasms
Interventions
Veliparib + VX-970 + Cisplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Bethesda, Maryland • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 23, 2026, 4:39 PM EDT
Suspended Not applicable Interventional

The Role of Ribose in Patients Diagnosed With Fibromyalgia

NCT00566514
View directory record Official record
Conditions
Fibromyalgia
Interventions
D-ribose, dextrose
Dietary Supplement · Other
Lead sponsor
Bioenergy Life Science, Inc.
Industry
Eligibility
18 Years to 78 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2008 · Synced Sep 23, 2026, 4:39 PM EDT